MindWalk Holdings Corp. (HYFT)
HYFT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-04-30, https://www.sec.gov/Archives/edgar/data/1715925/000119312526312694/0001193125-26-312694-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2026-04-30. Converted from CAD at 1.4258 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | HYFT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001715925 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $10.9M |
| Net income | -$9.8M |
| Operating income | Not in SEC XBRL data |
| Net margin | -89.7% |
| Operating margin | Operating income not reported |
| Revenue growth | -36.5% |
| Cash | $8.0M |
| Total assets | $15.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.1× |
Reported in CAD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company's ability to continue as a going concern." | 20-F 2026-07-23 |
| Cash and burn | 11.5M CAD cash; operating cash flow -3.1M CAD a quarter. | Report 2026-04-30 |
| Shares outstanding | 46,711,866 (2026-04-30); 46,154,118 a year earlier; 25,050,260 three years earlier. the newest SEC cover-page count is from 2026-04-30; shares issued since then are not in these figures. | Cover page 2026-04-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-07-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Davidson & Company LLP, Vancouver, Canada | PCAOB Form AP 2026-08-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-04-30 | 15.6M CAD | -13.9M CAD | -12.5M CAD | 11.5M CAD | No debt tags | 15.6M CAD | 20-F 2026-07-23 |
| FY 2025 2025-04-30 | 24.5M CAD | -30.2M CAD | -6.4M CAD | 10.8M CAD | No debt tags | 24.5M CAD | 20-F 2025-07-29 |
| FY 2024 2024-04-30 | 24.5M CAD | -26.1M CAD | -3.2M CAD | 3.5M CAD | No debt tags | 24.5M CAD | 20-F 2025-07-29 |
| FY 2023 2023-04-30 | 20.7M CAD | -26.6M CAD | -19.8M CAD | 8.4M CAD | No debt tags | 20.7M CAD | 20-F 2025-07-29 |
| FY 2022 2022-04-30 | 19.4M CAD | -16.7M CAD | -9.9M CAD | 30.0M CAD | No debt tags | 19.4M CAD | 20-F 2024-07-29 |
| FY 2021 2021-04-30 | 17.9M CAD | -7.3M CAD | -600K CAD | 41.8M CAD | No debt tags | 17.9M CAD | 40-F 2022-07-29 |
| FY 2020 2020-04-30 | 14.1M CAD | -4.9M CAD | -1.4M CAD | 2.7M CAD | 312K CAD | 14.1M CAD | 40-F/A 2021-09-29 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CAD.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2026-07-13 |
| Latest annual report | 20-F | 2026-07-23 |
| Latest quarterly / interim | 6-K | 2026-11-04 |
Source: SEC EDGAR submissions feed, 287 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.6% |
| 1 month | -33.1% |
| 3 months | -28.8% |
| Year to date | -45.6% |
| 1 year | -40.0% |
| From 52-week high | -64.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONCY | Oncolytics Biotech Inc. | $0.3399 | -8.14% | $44.6M |
| TLPH | Talphera Inc. | $0.8609 | -4.98% | $44.7M |
| NMAD | Nomad Power Solutions Inc. | $2.80 | +19.15% | $45.1M |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | $0.3650 | -29.81% | $45.4M |
| RNXT | RenovoRx Inc. | $0.9549 | -8.18% | $46.1M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| ANVS | Annovis Bio Inc. | $0.7500 | -19.02% | $46.5M |
| ATNM | Actinium Pharmaceuticals Inc. (Delaware) | $1.49 | -9.15% | $46.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier